enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Upadacitinib - Wikipedia

   en.wikipedia.org/wiki/Upadacitinib

   Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, ... [10] [11] Upadacitinib is a Janus kinase (JAK) ...

3. FDA Approves AbbVie's JAK Inhibitor Application For Active ...

   www.aol.com/news/fda-approves-abbvies-jak...

   The FDA approved AbbVie Inc's (NYSE: ABBV) Rinvoq (upadacitinib; 15 mg) for active psoriatic arthritis (PsA). Like Pfizer Inc's (NYSE: PFE) approval for Xeljanz, Rinvoq's approval also covers ...

4. AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU

   www.aol.com/news/abbvies-jak-inhibitor-rinvoq...

   AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.

5. Janus kinase inhibitor - Wikipedia

   en.wikipedia.org/wiki/Janus_kinase_inhibitor

   A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, [1] is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway in lymphocytes.

6. AbbVie's (ABBV) Rinvoq sNDA Decision Delayed by the FDA - AOL

   www.aol.com/news/abbvies-abbv-rinvoq-snda...

   The FDA will not meet its action dates for AbbVie's (ABBV) sNDAs for JAK inhibitor drug, Rinvoq (upadacitinib), for active psoriatic arthritis and active ankylosing spondylitis in adults.

7. AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's ... - AOL

   www.aol.com/news/abbvie-abbv-adds-fda-issued...

   AbbVie (ABBV) adds a heart-risk warning on the label of JAK inhibitor medicine, Rinvoq. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 ...

8. Psoriatic arthritis - Wikipedia

   en.wikipedia.org/wiki/Psoriatic_arthritis

   The JAK1 inhibitors tofacitinib (Xeljanz) and upadacitinib (Rinvoq) are approved for the use in active psoriatic arthritis. [34] The TYK2 inhibitor deucravacitinib (Sotyktu), which has been approved for plaque psoriasis, is currently undergoing a Phase II clinical trial to evaluate the efficacy and safety on psoriatic arthritis.

9. Common Causes of Arthritis for Women (& How to Treat It) - AOL

   www.aol.com/common-causes-arthritis-women-treat...

   Small molecule DMARDs, called JAK inhibitors, like tofacitinib (Xeljanz®) and upadacitinib (Rinvoq®) Colchicine to treat or prevent gout attacks. Antibiotics for bacterial infections.